Qualitative or quantitative defects of alpha-sarcoglycan

Qualitative or quantitative defects of alpha-sarcoglycan (also known as alpha-sarcoglycanopathy or limb-girdle muscular dystrophy type 2D/R3) is a rare inherited muscular dystrophy caused by mutations in the SGCA gene, which encodes the alpha-sarcoglycan protein. Alpha-sarcoglycan is a critical component of the dystrophin-associated glycoprotein complex (DGC), which provides structural stability to muscle cell membranes during contraction. When alpha-sarcoglycan is absent, reduced in quantity, or functionally abnormal, the muscle fiber membrane becomes fragile and susceptible to contraction-induced damage, leading to progressive muscle degeneration. The disease primarily affects the skeletal muscular system, with progressive weakness and wasting of the proximal limb-girdle muscles — particularly the hip and shoulder girdle musculature. Patients typically present in childhood with difficulty running, climbing stairs, and rising from the floor. Calf pseudohypertrophy is common. Serum creatine kinase levels are markedly elevated, often 10 to 100 times normal values. Disease severity is variable: some patients experience a severe Duchenne-like course with loss of ambulation in the first or second decade, while others have a milder phenotype with slower progression. Cardiac involvement is less common than in some other sarcoglycanopathies but can occur. Respiratory function may decline as the disease progresses. There is currently no cure for alpha-sarcoglycanopathy. Management is supportive and multidisciplinary, including physical therapy, orthopedic interventions, respiratory monitoring and support, and cardiac surveillance. Corticosteroids may be considered in some cases, though evidence is limited. Gene therapy approaches targeting the SGCA gene are under active investigation in clinical trials and represent a promising future therapeutic avenue.

Common questions about Qualitative or quantitative defects of alpha-sarcoglycan